Leadiant Biosciences is managed by a team of executives with exceptional experience in the all different aspects of the pharmaceutical business, with special expertise in the development, registration and commercialization of rare disease products.
Dr. Brughera is Chief Executive Officer and Global Head, Rare Disease of Leadiant Biosciences S.p.A. Dr. Brughera has extensive experience in R&D, business development and general management particularly in the oncology and rare disease areas across several global pharmaceutical, rare disease and biotech companies.
From January 2011 through October 2012, Dr. Brughera was Corporate Research and Development Managing Director of the Sigma-Tau Group. From 2004 to 2010, he served as the Vice President of Preclinical Development at Nerviano Medical Sciences S.r.l. (“NMS Group”), a pharmaceutical oncology-focused integrated R&D company. He also served as the Managing Director at Accelera S.r.l., an independent contract research organization affiliated with the NMS Group. From 1999 to 2004, Dr. Brughera held several senior level positions in the areas of Discovery and Development with Pharmacia Corporation and Pfizer, Inc. Prior to 1999, he held various positions at Pharmacia & Upjohn, Kabi-Pharmacia and Farmitalia Carlo Erba.
Dr. Brughera earned his degree in Veterinary Medicine from the University of Milan and is a European Registered Toxicologist. He attended Management Courses at Thunderbird American Graduate Business School at Arizona State University and MIT. He was EFPIA deputy topic leader for the ICH review of the Oncology Therapeutic Guidance. Publication record includes more 60 publications/communications.
He is currently Board Member of the following publically traded companies: Soligenix, Inc., Fennec Pharmaceuticals, Inc., and Lee’s Pharmaceutical Holdings Ltd. He was Board Member at Gentium from December 2011 to January 2014.
Mr. Deveque is Chief Financial Officer of Leadiant Biosciences S.p.A. He is responsible for the overall management of finance and administration of the rare disease business. Mr. Deveque has built strong expertise in international finance across both startups and global companies in the chemical, pharmaceutical and biotech industries including optimizing financial processes, streamlining organisations, designing and implementing strategic plans, setting-up financial-legal-tax structures at and monitoring business development activities including M&A, license and partnerships transactions.
Prior to joining the Group, in 2016, Mr. Deveque served as EMEA finance director at the European headquarters of Alexion Pharmaceuticals, finance director at Ecolab, chief financial officer at Sanofi and financial controller at Merck Sharpe and Dohme.
He holds a Master of Business Administration from Essec, the International Business School in Europe, with a major in finance.
Ms. Laureti is General Counsel of Leadiant Biosciences S.p.A. She is responsible for the overall management of legal and intellectual property assets including drafting and negotiating scientific and commercial agreements, licensing in and out, business acquisitions and joint ventures, antitrust and trade regulation, commercial dispute resolution, corporate governance as well as related matters.
Ms. Laureti joined the Group in 1998 as a business development associate prior to joining the corporate legal department. She has since held various roles with increasing responsibility.
Ms. Laureti worked in private practice with various law firms specialized in corporate and civil law. She earned her doctorate degree in Law from the University La Sapienza of Rome, Italy.
Dr. Noseda is the Chief Scientific Officer of Leadiant Biosciences S.p.A., where he is responsible for coordinating and managing scientific and discovery programs as well as evaluating new opportunities for the Leadiant Group. He joined the company in 1998 as Director of Scientific Office and Strategic Alliances within the Corporate R&D organization.
Dr. Noseda has significant experience in research and development and strategic/business operations across several therapeutic and diagnostic areas including high unmet medical need specialty areas such as cancer, immune-oncology and rare diseases. Prior to joining the Group he has held various managerial positions within the research and development and marketing departments of multinational corporations.
Dr. Noseda received his M.D in 1984 at the University of Milan and a Post Doctorate at Bowman Gray School of Medicine (USA).
